Phosphatidylserine-dependent neuroprotective signaling promoted by docosahexaenoic acid

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 82, Issue 4-6, 2010, Pages 165-172

  Kim, Hee Yong ^a   Akbar, Mohammed ^a   Kim, Yang Suk ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; PHOSPHATIDYLSERINE; PROTEIN KINASE B; PROTEIN KINASE C; RAF PROTEIN;

ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; NERVE CELL MEMBRANE; NERVE CELL NECROSIS; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; SIGNAL TRANSDUCTION; SUPPLEMENTATION;

ANIMALS; APOPTOSIS; DOCOSAHEXAENOIC ACIDS; HUMANS; MODELS, BIOLOGICAL; NEURONS; NEUROPROTECTIVE AGENTS; PHOSPHATIDYLSERINES; PHOSPHORYLATION; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 77952103357     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2010.02.025     Document Type: Article

References (66)

1. Salem N. Omega-3 Fatty Acids: Molecular and Biochemical Aspects 1989, Alan R. Liss, New York, pp 109-228.
2. Kim H.Y. Novel metabolism of docosahexaenoic acid in neural cell. J. Biol. Chem. 2007, 282:18661-18665.
3. Willatts P., Forsyth J.S., Di Modugno M.K., Varma S., Colvin M. Effect of long-chain polyunsaturated fatty acids in infant formula on problem solving at 10 months of age. Lancet 1998, 352:688-691.
4. Birch E.E., Garfield S., Hoffman D.R., Uauy R.D., Birch D.G. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Dev. Med. Child Neurol. 2000, 42:174-181.
5. Gamoh S., Hashimoto M., Sugioka K., Shahdat Hossain M., Hata N., Misawa Y., Masumura S. Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience 1999, 93:237-241.
6. Moriguchi T., Greiner R.S., Salem N. Behavioral deficits associated with dietary induction of decreased brain docosahexaenoic acid concentration. J Neurochem. 2000, 75:2563-2573.
7. Catalan J., Moriguchi T., Slotnick B., Murthy M., Greiner R.S., Salem N. Cognitive deficits in docosahexaenoic acid-deficient rats. Behav. Neurosci. 2002, 116:1022-1031.
8. McNamara R.K., Hahn C.G., Jandacek R., Rider T., Tso P., Stanford S.K. Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. Biol. Psychiatry 2007, 62:17-24.
9. Martinez M. Severe deficiency of docosahexaenoic acid in peroxisomal dis ordersa defect of delta 4 desaturation?. Neurology 1990, 40:1292-1298.
10. Soderberg M., Edlund C., Kristensson K., Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991, 26:421-425.
11. Martinez M., Vazquez E., Garcia-Silva M.T., Manzanares J., Bertran J.M., Castello F., Mougan I. Therapeutic effects of docosahexaenoic acid ethylester in patients with generalized peroxisomal disorders. Am. J. Clin. Nutr. 2000, 71:376S.
12. Freeman M.P., Hibbeln J.R., Wisner K.L., Davis J.M., Mischoulon D., Peet M., et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J. Clin. Psychiatry 2006, 67:1954-1967.
13. Calon F., Lim G.P., Yang F., Morihara T., Teter B., Obeda O., Rostaing P., Triller A., Salem N., Ashe K.H., Frautschy S.A., Cole G.M. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004, 43:633-645.
14. Okada M., Amamoto T., Tomonaga M., Kawachi A., Yazawa K., Mine K., Fujiwara M. The chronic administration of docosahexaenoic acid reduces the spatial cognitive deficit following transient forebrain ischemia in rats. Neuroscience 1996, 71:17-25.
15. Kim H.Y., Akbar M., Lau A., Edsall L. Inhibition of neuronal apoptosis by docosahexaenoic acid (22:6n-3): role of phosphatidylserine in anti-apoptotic effect. J. Biol. Chem. 2000, 275:35215-35223.
16. Akbar M., Kim H.Y. Protective effects of docosahexaenoic acid (DHA) in staurosporine-induced apoptosis: involvement of wortmanin-sensitive path-way. J. Neurochem. 2002, 82:655-665.
17. Akbar M., Calderon F., Wen Z., Kim H.Y. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl. Acad. Sci. USA 2005, 102:10858-10863.
18. Kawakita E., Hashimoto M., Shido O. Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience 2006, 139:991-997.
19. Calderon F., Kim H.K. Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J. Neurochem. 2004, 90:979-988.
20. Cao D., Kevala K., Kim J., Moon H.S., Jun S.B., Lovinger D., Kim H.Y. Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function. J. Neurochem. 2009, 111:510-521.
21. Yavin E., Himovichi E., Eilam R. Delayed cell migration in the developing rat brain following maternal Omega 3 alpha linolenic acid dietary deficiency. Neuroscience 2009, 162:1011-1022.
22. Kanfer.J.N. The base exchange enzymes and phospholipase D of mammalian tissue. Can. J. Biochem. 1980, 5:81370-81380.
23. Vance J.E., Steenbergen R. Metabolism and functions of phosphatidylserine. Prog. Lipid Res. 2005, 44:207-234.
24. Kuge O., Nishijima M. Phosphatidylserine synthase I and II of mammalian cells. Biochim. Biophys. Acta. 1997, 1348:151-156.
25. Kuge O., Saito K., Nishijima M. Cloning of a Chinese hamster ovary (CHO) cDNA encoding phosphatidylserine synthase (PSS) II, overexpression of which suppresses the phosphatidylserine biosynthetic defect of a PSS I-lacking mutant of CHO-K1 cells. J. Biol. Chem. 1997, 272:19133-19139.
26. Stone J., Cui Z., Vance J.E. Cloning and expression of mouse liver phosphatidylserine synthase-1 cDNA. Overexpression in rat hepatoma cells inhibits the CDP-ethanolamine pathway for phosphatidylethanolamine biosynthesis. J. Biol. Chem. 1998, 273:7293-7302.
27. Voelker D.R. Phosphatidylserine decarboxylase. Biochim. Biophys. Acta 1997, 1348:236-244.
28. Kim H.Y., Bigelow J., Kevala J.H. Substrate preference in phosphatidylserine biosynthesis for docosahexanoic acid containing species. Biochemistry 2004, 43:1030-1036.
29. Hamilton J., Greiner R., Salem.N., Kim H.Y. N-3 fatty acid deficiency decrease phosphatidylserine accumulation selectively in neuronal tissues. Lipids 2000, 35:863-869.
30. Murthy M., Hamilton J., Greiner R.S., Moriguchi T., Salem N., Kim H.Y. Differential effects of n-3 fatty acid deficiency on phospholipids molecular species composition in the rat hippocampus. J. Lipid Res. 2002, 43:611-617.
31. Kim H.Y., Akbar M., Lau A. Effects of docosapentaenoic acid on neuronal apoptosis. Lipids 2003, 38:453-457.
32. Galli C., Trzeciak.H.I., Paoletti R. Effects of dietary fatty acids on the fatty acid composition of brain ethanolamine phosphoglyceride: Reciprocal replacement of n-6 and n-3 polyunsaturated fatty acids. Biochim. Biophys. Acta (BBA)-Lipids Lipid Metab. 1971, 248:449-454.
33. Guo M., Stockert L., Akbar M., Kim H.Y. Neuronal specific increase of phosphatidylserine by docosahexaenoic acid. J. Mol. Neurosci. 2007, 33:67-73.
34. Bourre J.M., Faivre A., Dumont O., Nouvelot A., Loudes C., Puymirat J., Tixier-Vidal A. Effect of polyunsaturated fatty acids on fetal mouse brain cells in culture in a chemically defined medium. J. Neurochem. 1983, 41:1234-1242.
35. Contestabile A. Cerebellar granule cells as a model to study mechanisms of neuronal apoptosis or survival in vivo and in vitro. Cerebellum 2002, 1:41-55.
36. Boni.L.T., Rando R.R. The nature of protein kinase C activation by physically defined phospholipid vesicles and diacylglycerols. J. Biol. Chem. 1985, 260:10819-10825.
37. Newton A.C., Keranen L.M. Phophatidyl-l-serine is necessary for protein kinase C's high-affinity interaction with diacylglycerol-containing membranes. Biochemistry 1994, 33:6651-6658.
38. Verdaguer N., Corbalan-Garcia S., Ochoa W.F., Fita I., Gomez-Fernandez.J.C. Ca(2+) bridges the C2 membrane-binding domain of protein kinase Calphα directly to phosphatidylserine. EMBO J. 1999, 18:6329-6338.
39. Improta-Brears T., Ghosh S., Bell R.M. Mutational analysis of Raf-1 cysteine rich domain: requirement for a cluster of basic aminoacids for interaction with phosphatidylserine. Mol. Cell Biochem. 1999, 198:171-178.
40. Ghosh S., Strum J.C., Sciorra V.A., Daniel L., Bell R.M. R. Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid. Phosphatidic acid regulates the translocation of Raf-1 in 12-O-tetradecanoylphorbol-13-acetate-stimulated Madin-Darby canine kidney cells. J. Biol. Chem. 1996, 271:8472-8480.
41. Brazil D.P., Hemmings B.A. Ten years of protein kinase B signalling: a hard Akt to Follow. Trends Biochem. Sci. 2001, 26:657-664.
42. Alessi D.R., Cohen P. Mechanism of activation and function of protein kinase B. Curr. Opin. Genet. Dev. 1998, 8:55-62.
43. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 1998, 10:262-267.
44. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTor complex. Science 2005, 307:1098-1101.
45. Thiel G., Ekici M., Rossler O.G. Regulation of cellular proliferation,differentiation and cell death by activated Raf. Cell Commun. Signal. 2009, 7:8.
46. Wellbock C., Karasarides M., Marais R. The Raf proteins take centre stage. Nat. Rev. Mol. Cell Biol. 2004, 5:875-885.
47. D. Stokoe, S.G. Macdonald, K. Cadwallader, M. Symons, J.F. Hancock. Activation of Raf as a result of recruitment to the plasma membrane. Science 264 (1994) 1463-1467; Correction, Science 266 (1994) 1792-1793.
48. Leevers S.J., Paterson H.F., Marshall C.J. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 1994, 369:411-414.
49. King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S., Marshall M.S. The protein kinase Pak3 positively regulates Raf-1 through phosphorylation of serine 338. Nature 1998, 396:180-183.
50. Ballif B.A., Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ. 2001, 12:397-408.
51. Huser M., Luckett J., Chiloeches A., Mercer K., Iwobi M., Giblett S., Sun X.M., Brown J., Marais R., Pritchard C. MEK kinase activity is not necessary for Raf-1 function. EMBO J. 2001, 20:1940-1951.
52. Liu L., Xie L.Y., Lou L. PI3K is required for insulin-stimulated but not EGF-stimulated ERK1/2 activation. Eur. J. Cell Biol. 2006, 85:367-374.
53. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 1995, 9:484-496.
54. Goodnight J.A., Mischak H., Kolch W., Mushinski J.F. Immunocytochemical localization of eight protein kinase C isozymes overexpressed in NIN 3T3 fibroblasts: isoform-specific association with microfilaments, Golgi, endoplasmic reticulum, and nuclear and cell membranes. J. Biol. Chem. 1995, 270:9991-10001.
55. Gutcher I., Webb P.R., Anderson N.G. The isoform specific regulation of apoptosis by protein kinase C. Cell. Mol. Life Sci. 2003, 60:1061-1070.
56. Goodnight J.A., Mischak H., Mushinski J.F. Selective involvement of protein kinase C isozymes in differentiation and neoplastic transformation. Adv. Cancer Res. 1994, 64:159-209.
57. Papp H., Czifra G., Bodó E., Lázár J., Kovács I., Aleksza M., Juhász I., Ács P., Sipka S., Kovács L., Blumberg P.M., Bíró T. Opposite roles of protein kinase C isoforms in proliferation, differentiation, apoptosis, and tumorigenicity of human HaCaT keratinocytes. Cell. Mol. Life Sci. 2004, 61:1095-1105.
58. Newton A.C. Lipid activation of protein kinases. J. Lipid. Res. 2009, 50:S266-S271.
59. Mosior M., Newton A.C. Mechanism of apparent cooperativity in the interaction of protein kinase C with phosphatidylserine. Biochemistry 1998, 37:17271-17279.
60. Verdaguer N., Corbalan-Garcia1 S., Ochoa W.F., Fita I., Gomez-Fernandez J.C. Ca2+ bridges the C2 membrane-binding domain of protein kinase Cα directly to phosphatidylserine. EMBO J. 1999, 18:6329-6338.
61. Johnson J.E., Giorgione J., Newton A.C. The C1 and C2 domains of protein kinase C are independent membrane targeting modules, with specificity for phosphatidylserine conferred by the C1 domain. Biochemistry 2000, 39:11360-11369.
62. Moelling K., Schad K., Bosse M., Zimmermann S., Schweneker M. Regulation of Raf-Akt Cross-talk. J Biol. Chem. 2002, 277:31099-31106.
63. Zimmermann S., Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999, 286:1741-1744.
64. Rommel C., Clarke B.A., Zimmerman S., Nunez L., Rossman R., Reid K., Moelling K., Yancopoulos G.D., Glass D.J. Differentiation stage specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 1999, 286:1738-1741.
65. Corbit K.C., Trakul N., Eves E.M., Diaz B., Marshall M., Rosner M.R. Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J. Biol. Chem. 2003, 278:13061-13068.
66. Weyrich P., Neuscheler D., Melzer M., Hennige A.M., Häring H.U., Lammers R. The Par6alpha/αPKC complex regulates Akt1 activity by phosphorylating Thr34 in the PH-domain. Mol. Cell Endocrinol. 2007, 268:30-36.